January 2005

Anti-Ulcer Agents and Acid Suppressants

Nexium (esomeprazole) Capsules

Producer: AstraZeneca

Drug Favorable reception Categorization: Supplemental New Drug Application program (Approval Date: 11/24/04)

New Reading: This supplemental new drug action provides for the use of Nexium (esomeprazole) delayed-release capsules for the risk reaction of nonsteroidal anti-inflammatory drug (NSAID)-associated gastric ulcers.

Dosing: Esomeprazole 20 or 40 mg once daily

Clinical Summary: In 2 multicenter, double-blind, placebo-controlled studies, esomeprazole was studied in 1429 endoscopically confirmed nonulcerous patients at risk of developing gastric and/or duodenal ulcers associated with continuous use of non-selective and COX-2 selective NSAIDs.
Patients receiving NSAIDs and treated with esomeprazole 20 mg or 40 mg once daily experienced significant reducing in gastric ulcer occurrences soul to vesper idiom at 26 weeks.
No additional goodness was seen with esomeprazole 40 mg over esomeprazole 20 mg.
This is a part of article January 2005 Taken from "Nexium Generic Esomeprazole" Information Blog